Caribou Biosciences, Inc.
CRBUHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Caribou Biosciences, Inc. focuses on Biotechnology services and products. Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. Valued at $168.3M, CRBU is a micro-cap name in its sector. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies.
Market Cap
$168.3M
Beta
2.28
P/E (TTM)
—
P/E (Fwd)
-1.24
EPS (TTM)
$-1.08
EPS (Fwd)
$-1.26
ROE
-78.3%
ROA
-36.9%
Cash
$112.3M
Total Debt
$26.7M
Free CF
-$59.6M
52W Change
-14.7%
Annual Financials
Cash vs Debt
Where CRBU stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CRBU finished 12.09% below its 150-day moving average ($1.82) and 11.11% below its 200-day moving average ($1.80). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CRBU overbought or oversold?
At the September 3, 2026 close, CRBU's RSI(14) was 49.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $112.3M in cash and $26.7M in debt, CRBU maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$59.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -78.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $13.9M to $11.2M.
Caribou Biosciences, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing CRBU's risk profile alongside its fundamentals and technical indicators provides a more complete picture.